FindTrial
Sign In

PEGylated Recombinant Human Hyaluronidase (PEGPH20)

DRUG3 trials

Sponsors

Scripps Health, Hoffmann-La Roche, PH Research, S.L.

Conditions

Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal CarcinomaPancreatic Adenocarcinoma Non-resectablePancreatic CancerPancreatic Ductal Adenocarcinoma

Early Phase 1

A Trial of PEGPH20 in Combination With Avelumab in Chemotherapy Resistant Pancreatic Cancer
TerminatedNCT03481920
PH Research, S.L.Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma
Start: 2018-01-10End: 2019-06-10Updated: 2019-08-22

Phase 1

A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)
CompletedNCT03281369
Hoffmann-La RocheGastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma
Start: 2017-10-13End: 2025-10-09Updated: 2025-12-15

Phase 2

PEGPH20 Plus Gemcitabine With Radiotherapy in Patients With Localized, Unresectable Pancreatic Cancer
TerminatedNCT02910882
Scripps HealthPancreatic Adenocarcinoma Non-resectable
Start: 2017-01-03End: 2018-08-31Updated: 2019-04-11

Related Papers

First-line tiragolumab plus atezolizumab and chemotherapy in patients with previously untreated, locally advanced unresectable or metastatic oesophageal cancer (MORPHEUS-EC): a randomised, open-label, phase 1b/2 trial.
2026-01-01
MORPHEUS-EC: A phase Ib/II open-label, randomized study of first-line tiragolumab (tira) + atezolizumab (atezo) + chemotherapy (CT) in patients (pts) with esophageal cancer (EC).
Journal of Clinical Oncology2024-01-206 citations
Atezolizumab Plus PEGPH20 Versus Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma and Gastric Cancer: MORPHEUS Phase Ib/II Umbrella Randomized Study Platform
The Oncologist2023-03-2048 citations
Abstract CT201: Phase Ib/II open-label, randomized evaluation of atezolizumab + cobimetinib vs control in MORPHEUS-NSCLC (non-small cell lung cancer), MORPHEUS-PDAC (pancreatic ductal adenocarcinoma) and MORPHEUS-GC (gastric cancer)
Cancer Research2020-08-154 citations
Phase Ib/II open-label, randomized evaluation of 2L atezolizumab (atezo) + PEGPH20 versus control in MORPHEUS-pancreatic ductal adenocarcinoma (M-PDAC) and MORPHEUS-gastric cancer (M-GC).
Journal of Clinical Oncology2020-05-208 citations
Phase Ib/II open-label, randomized evaluation of 2L atezolizumab (atezo) + BL-8040 versus control in MORPHEUS-pancreatic ductal adenocarcinoma (M-PDAC) and MORPHEUS-gastric cancer (M-GC).
Journal of Clinical Oncology2020-02-017 citations
MORPHEUS: A phase Ib/II study platform evaluating the safety and clinical efficacy of cancer immunotherapy (CIT)–based combinations in gastrointestinal (GI) cancers.
Journal of Clinical Oncology2019-01-2914 citations
MORPHEUS: A phase Ib/II umbrella study platform evaluating the safety and efficacy of multiple cancer immunotherapy (CIT)-based combinations in different tumour types
Annals of Oncology2018-10-0119 citations
Abstract 2740: PEGylated recombinant hyaluronidase PH20 (pegvorhyaluronidase alfa PEGPH20) converts HA-rich tumors from resistant to sensitive to anti-PD-L1 immunotherapy in murine syngeneic breast cancer models
Cancer Research2018-07-012 citations
MORPHEUS: A phase Ib/II trial platform evaluating the safety and efficacy of multiple cancer immunotherapy (CIT) combinations in patients (pts) with gastric or pancreatic cancer.
Journal of Clinical Oncology2018-05-208 citations
MORPHEUS: A phase Ib/II multi-trial platform evaluating the efficacy and safety of cancer immunotherapy (CIT)-based combinations in patients (pts) with gastric or pancreatic cancer.
Journal of Clinical Oncology2018-02-018 citations